Methallylescaline
| Clinical data | |
|---|---|
| Other names | MAL; 4-Methylallyloxy-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-methylallyloxyphenethylamine |
| Routes of administration | Oral |
| Drug class | Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Duration of action | 12–16 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H21NO3 |
| Molar mass | 251.326 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Methallylescaline, abbreviated as MAL and also known as 4-methylallyloxy-3,5-dimethoxyphenethylamine, is a lesser-known psychedelic drug. It is the 4-methyl analog of allylescaline. MAL was first synthesized by Alexander Shulgin. It has been sold as a designer drug.